Corrado A, Ferrari S M, Ferri C, Ferrannini E, Antonelli A, Fallahi P
Department of Clinical and Experimental Medicine, University of Pisa.
Department of Medical, Surgical, Maternal, Pediatric and Adult Sciences, University of Modena and Reggio Emilia, Italy.
Clin Ter. 2014;165(2):e181-5. doi: 10.7471/CT.2014.1706.
The upregulation of (C-X-C motif) receptor 3 (CXCR3) and its ligand (C-X-C motif) ligand (CXCL)10 (CXCL10) has been documented in many autoimmune disorders. Many studies have suggested that the CXCL10/CXCR3 axis plays a critical role in the autoimmune process and in β-cell destruction in Type 1 Diabetes (T1D). Serum CXCL10 level "Th1 chemokine" is high in T1D patients, and this suggests that CXCL10 may be a candidate for a predictive marker of T1D. Furthermore, serum CXCL10 levels measurement may be useful to assess the pathophysiology of the disease course in T1D. Blocking of the CXCL10 chemokine expression in newly onset of diabetes seems to be a possible approach for the therapy of T1D. Further studies are needed to investigate interactions between chemokines and cytokines in the pathogenesis of T1D.
在许多自身免疫性疾病中，已证实（C-X-C基序）受体3（CXCR3）及其配体（C-X-C基序）配体10（CXCL10）的上调。许多研究表明，CXCL10/CXCR3轴在自身免疫过程以及1型糖尿病（T1D）的β细胞破坏中起关键作用。T1D患者血清CXCL10水平（“Th1趋化因子”）较高，这表明CXCL10可能是T1D预测标志物的候选者。此外，测量血清CXCL10水平可能有助于评估T1D病程的病理生理学。在糖尿病新发病例中阻断CXCL10趋化因子表达似乎是T1D治疗的一种可能方法。需要进一步研究来调查趋化因子和细胞因子在T1D发病机制中的相互作用。
